IN THE CLAIMS

Please AMEND the claims as follows:

- 1. (Currently Amended): A method to treat hyperactive sebaceous gland disorders, other than acne, in a subject <u>in need thereof</u> by:
- (i) topically applying a hydrophobic and/or lipophilic photosensitizer composition to skin tissue of said subject exhibiting symptoms of a hyperactive sebaceous gland disorder, and
- (ii) exposing the tissue of said subject to light energy at a wavelength capable of activating the photosensitizer and at a fluence rate between about 0.1 mW/cm² and about 600mW/cm².

wherein said photosensitizer is other than 5-aminolevulinic acid and <u>analogs</u> derivatives thereof.

- 2. (previously presented): The method of claim 1, wherein the disorder is seborrhea, seborrheic dermatitis, or sebaceous gland hyperplasia.
- 3. (previously presented): The method of claim 1, wherein the photosensitizer is a lipophilic photosensitizer.
- 4. (previously presented): The method of claim 1, wherein the photosensitizer is a hydrophobic photosensitizer.
- 5. (previously presented): The method of claim 1, wherein the photosensitizer is (a) a porphyrin or derivative thereof, (b) a methylene blue or derivative thereof, (c) a bacteriochlorophyll or derivative thereof, or a combination of any of (a) (c).
- 6. (previously presented): The method of claim 1, wherein the photosensitizer is (a) a chlorin, (b) a bacteriochlorin, (c) an isobacteriochlorin, (d) a phthalocyanine, (e) a naphthalocyanine, (f) a pyropheophorbide, (g) a sapphyrin, (h) a texaphyrin, (i) a tetrahydrochlorin, (j) a purpurin, (k) a porphycene, (1) a phenothiazinium, (m) a bacteriochlorophyll, (n) a bacteriochlorophyll derivative, (o) a pro-porphyrin, (p) a porphyrin, or a combination of any of (a) (p).
 - 7. (previously presented): The method of claim 1, wherein the photosensitizer is (a)

of (a)-verteporfin, (b) of (a)-lemuteporfin, or a combination of (a) and (b).

- 8. (previously presented): The method of claim 1, wherein the composition has a viscosity at 20°C of from about 50 cps to about 50000 cps.
- 9. (previously presented): The method of claim 1, wherein excess photosensitizer composition is removed from the skin prior to application of activation energy.
 - 10. (canceled)
- 11. (previously presented): The method of claim 1, wherein steps i) and ii) are repeated at least about once every six months.
- 12. (previously presented): The method of claim 1, wherein steps i) and ii) are repeated at least about once every three months.
- 13. (previously presented): The method of claim 1, wherein steps (i) and (ii) are repeated at intervals of not less than about 5 days.

Claims 14-17. (canceled):

- 18. (previously presented): The method of claim 1, wherein said energy is at least in part supplied by a light emitting diode device.
- 19. (previously presented): The method of claim 18, wherein said device emits red and blue light.

20-21. (canceled)

- 22. (previously presented): The method of claim 7, wherein the photosensitizer is lemuteporfin.
- 23. (currently amended): A method to treat hyperactive <u>sebaceous</u> gland disorders, other than acne, in a subject in need thereof by:
- (i) topically applying a photosensitizer composition comprising lemuteporfin to skin tissue <u>of said subject</u> exhibiting symptoms of a hyperactive <u>sebaceous</u> gland disorder, and

(ii) exposing the tissues of said subject to light energy at a wavelength capable of activating the lemuteporfin and at a fluence rate between about 0.1 mW/cm^2 and about 600mW/cm^2 .